glp 1 for cardiovascular health Semaglutide Shows Secondary Prevention Benefits in Patients Without Diabetes Cardiovascular disease continuum-GLP-1 action. Adapted

A 35-year-old CrossFit competitor in Vancouver underwent rotator cuff repair surgery four weeks ago

Science 343 , 408411 (2014)

data collected from industry sources and key stakeholders has been properly cross-validated

Participants stigmatized an individual who had regained weight after using a GLP-1, rating them less favorably than an individual who had lost weight and maintained it (i.e., higher in negative traits, lower in positive traits, more unhealthy, less willing to affiliate) and less favorably, again, than even an individual who had not attempted weight loss (i.e., lower in positive traits)

The honest position on human evidence is that it is thin

Shmerling, MD, Senior Faculty Editor, Harvard Health Publishing